FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to focus on safety concerns in the decisive meeting.
Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness.
